KIRIN PHARMA Canadian Trademark Information

On Friday, December 29, 2006, a canadian trademark registration was filed for KIRIN PHARMA by KIRIN HOLDINGS KABUSHIKI KAISH *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1329915. The current status of this trademark filing is Registration published. The KIRIN PHARMA trademark is filed in the description of Antibodies; reagents for scientific research namely, reagents that are used to identify DNA types, reagents that are used to identify the type of bacteria, reagents that are used to isolate, detect, quantify, identify or assay protein, reagents that are used to isolate, detect, quantify, identify or assay compound including nucleic acid, reagents that are used to detect nucleic acid mutation in polynucleic acid, reagents that are used to detect, quantify, identify or assay a certain bacteria, reagents that are labeled with stable isotope, reagents that are used to isolate, detect, quantify, identify or assay cell and enzyme, reagents that are a labeled antibody, reagents that are used to transfect compound including peptide and nucleic acid into cell, reagents that are used to test immune response in blood, reagents that are used to test drug concentration in the plasma and the serum, reagents that are used to identify a risk factor for cancer, reagents that are used to detect, quantify, identify, assay detect drugs in urine sample; pharmaceutical preparation for treatment of anemia; pharmaceutical preparations for treatment of leukopenia; pharmaceutical preparations for treatment of thrombocytopenia; pharmaceutical preparations for mobilization of peripheral blood progenitor cell; pharmaceutical preparations for treatment of hyperphosphatemia; pharmaceutical preparations for treatment of hyperparathyroidism; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treatment of leukemia; pharmaceutical preparations for treatment of influenza; pharmaceutical preparations for treatment of HIV; pharmaceutical preparations for treatment of myelodysplastic syndrome; pharmaceutical preparations for treatment of hepatitis virus infection; pharmaceutical preparations for treatment of autoimmune hepatitis; pharmaceutical preparations for conditioning treatment prior to hematopoietic stem cell transplantation; diagnostic preparations and reagents, namely for clinical or medical laboratory use, for medical diagnostic use, for medical research use; pre-filled syringes; injectors or syringes for medical purposes; injection needles; blood transfusion apparatus, namely transfusion bags and blood filters; infusion apparatus for therapeutic purposes, namely programmable infusion pumps, manual injectors, infusion needle and luer connectors. , Development of new technology for others in the field of human antibodies and biotechnology; research, namely, testing and inspection of pharmaceuticals, cosmetics and foodstuffs. , Development of new technology for others in the field of human antibodies and biotechnology; research, namely, testing and inspection of pharmaceuticals, cosmetics and foodstuffs. , Antibodies; reagents for scientific research namely, reagents that are used to identify DNA types, reagents that are used to identify the type of bacteria, reagents that are used to isolate, detect, quantify, identify or assay protein, reagents that are used to isolate, detect, quantify, identify or assay compound including nucleic acid, reagents that are used to detect nucleic acid mutation in polynucleic acid, reagents that are used to detect, quantify, identify or assay a certain bacteria, reagents that are labeled with stable isotope, reagents that are used to isolate, detect, quantify, identify or assay cell and enzyme, reagents that are a labeled antibody, reagents that are used to transfect compound including peptide and nucleic acid into cell, reagents that are used to test immune response in blood, reagents that are used to test drug concentration in the plasma and the serum, reagents that are used to identify a risk factor for cancer, reagents that are used to detect, quantify, identify, assay detect drugs in urine sample; pharmaceutical preparation for treatment of anemia; pharmaceutical preparations for treatment of leukopenia; pharmaceutical preparations for treatment of thrombocytopenia; pharmaceutical preparations for mobilization of peripheral blood progenitor cell; pharmaceutical preparations for treatment of hyperphosphatemia; pharmaceutical preparations for treatment of hyperparathyroidism; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treatment of leukemia; pharmaceutical preparations for treatment of influenza; pharmaceutical preparations for treatment of HIV; pharmaceutical preparations for treatment of myelodysplastic syndrome; pharmaceutical preparations for treatment of hepatitis virus infection; pharmaceutical preparations for treatment of autoimmune hepatitis; pharmaceutical preparations for conditioning treatment prior to hematopoietic stem cell transplantation; diagnostic preparations and reagents, namely for clinical or medical laboratory use, for medical diagnostic use, for medical research use; pre-filled syringes; injectors or syringes for medical purposes; injection needles; blood transfusion apparatus, namely transfusion bags and blood filters; infusion apparatus for therapeutic purposes, namely programmable infusion pumps, manual injectors, infusion needle and luer connectors. .